Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide, affecting an estimated 1·3 billion adults.1 Although most patients ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

Please provide your email address to receive an email when new articles are posted on . After a hyperkalemia event, mineralocorticoid receptor antagonists were discontinued in up to 46% of patients.

Arginine vasopressin (AVP), also known as antidiuretic hormone, is a nonapeptide secreted from the posterior pituitary gland. The primary stimulus for the secretion of AVP is a rise in serum ...

Please provide your email address to receive an email when new articles are posted on . An updated clinical practice guideline suggested screening all people with hypertension for primary ...

Diabetics aided by spironolactone with ACE inhibitors, angiotensin receptor. The renin-angiotensin-aldosterone system (RAAS) is a well-known regulator of BP, and angiotensin II (AII) plays the primary ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Aldosterone suppression testing is suggested where screening results indicate an intermediate probability for lateralizing PA and patients wish to pursue eligibility for surgical therapy. HealthDay ...